Hair Loss & Restoration and Platelet-rich plasma (PRP): what the trial registry contains
The ClinicalTrials.gov registry holds 26 records for PRP in Hair Loss & Restoration: 2 recruiting now, 3 labelled Phase 3 or 4, across 7 countries. Snapshot 2026-08-29.
Why this is studied in Hair Loss & Restoration
Androgenetic alopecia is a hormone-driven miniaturisation of follicles, not follicle death, which is why regenerative approaches are biologically plausible: the target still exists. It is also the one tracked indication where exosome registrations outnumber whole-cell studies, reflecting how quickly aesthetic markets adopt cell-free products.
What PRP means in this table
Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.
The numbers
Every figure below comes from one reproducible query (androgenetic alopecia x platelet-rich plasma) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 26 |
| Interventional studies in the sample | 24 |
| Recruiting right now | 2 |
| Completed | 10 |
| Terminated, withdrawn or suspended | 2 |
| Phase 3 or Phase 4 records | 3 |
| Countries with at least one site | 7 |
| Median planned enrolment | 30 participants |
| Largest single planned enrolment | 201 participants |
| First / most recent start year | 2011 — 2026 |
How mature is this evidence?
The field has produced some later-stage designs — 3 of the 26 records carry a Phase 3 or 4 label — but the bulk of activity remains earlier-phase safety and signal-finding work.
2 of these records (8%) were terminated, withdrawn or suspended, against 10 marked completed; unfinished studies rarely appear in marketing summaries.
| Phase label | Records | Share |
|---|---|---|
| Not applicable | 12 | 41% |
| Phase 2 | 8 | 28% |
| Early Phase 1 | 3 | 10% |
| Phase 4 | 3 | 10% |
| Phase 1 | 3 | 10% |
Median planned enrolment is 30 participants (largest single study: 201). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Sites are spread across 7 countries, with United States accounting for roughly 35% of country mentions — geography reflects where regulators permit this work and where sponsors sit, not where care is best.
| Country | Studies with a site there |
|---|---|
| United States | 7 |
| Indonesia | 3 |
| Egypt | 3 |
| China | 3 |
| Pakistan | 2 |
| Spain | 1 |
| Canada | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Funding profile: 7 academic or hospital sponsors against 1 commercial ones — academic overall, which is worth knowing before reading any single positive report.
- Indonesia University — 2 records
- Sohag University — 2 records
- Faculty Hospital Kralovske Vinohrady — 1 record
- Montefiore Medical Center — 1 record
- Icahn School of Medicine at Mount Sinai — 1 record
- Kimberly Meathrel — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07429253 — Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients | Phase 1, Phase 2 | Recruiting | 40 | PT. Prodia Stem Cell Indonesia | 2026-01-09 |
| NCT07335367 — PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A Study | Phase 2 | Recruiting | 76 | Nanfang Hospital, Southern Medical University | 2026-01-09 |
| NCT06043349 — Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination in Male Androgenetic Alopecia | Phase 4 | Unknown | 36 | Indonesia University | 2023-06-01 |
| NCT03388840 — Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction | Phase 4 | Unknown | 40 | Assiut University | 2018-01-15 |
| NCT02999737 — Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia | Phase 4 | Unknown | 40 | Skin Care and Laser Physicians of Beverly Hills | 2016-11 |
| NCT07348315 — Effectiveness of Apheresis Platelet-Rich Plasma Injection for Androgenic Alopecia | Phase 2 | Completed | 201 | zhang li | 2023-09-01 |
| NCT06239207 — Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia | Phase 2 | Completed | 30 | Services Hospital, Lahore | 2023-09-21 |
| NCT05348343 — Activated PRP for Treatment of Androgenetic Alopecia | Phase 1, Phase 2 | Completed | 17 | Santiste Medical Inc. | 2022-05-17 |
| NCT03048461 — The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia | Phase 2 | Withdrawn | n/a | Northwestern University | 2019-06 |
| NCT02865421 — Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia | Phase 2 | Completed | 22 | King Edward Medical University | 2017-06-10 |
What this page does and does not tell you
Registration counts measure activity, not effect. A study appears here the moment it is registered — before any participant is enrolled, and regardless of whether results are ever posted.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many PRP studies for Hair Loss & Restoration are recruiting right now?
2 of 26 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is PRP an approved treatment for Hair Loss & Restoration?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 26 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on PRP for Hair Loss & Restoration?
3 of 26 records carry a Phase 3 or Phase 4 label and 10 are marked completed. Registrations run from 2011 to 2026.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.